Double stranded oligonucleotide for modulating JAK1 expression

TW202639853APending Publication Date: 2026-10-01F HOFFMANN LA ROCHE & CO AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114149382
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-12-17
Filing Date
2025-12-16
Publication Date
2026-10-01

Smart Images

  • Figure TWG2TA001078821_001
    Figure TWG2TA001078821_001
  • Figure TWG2TA001078821_002
    Figure TWG2TA001078821_002
  • Figure TWG2TA001078821_003
    Figure TWG2TA001078821_003
Patent Text Reader

Abstract

The present invention relates to double stranded oligonucleotides that are complementary to JAK1, leading to modulation of the expression of JAK1. Modulation of JAK1 expression is beneficial for a range of medical disorders including dry eye disease, inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), cancer, myelofibrosis, and asthma. Also included are compositions comprising the double stranded oligonucleotide and methods of treatment using the double stranded oligonucleotide.
Need to check novelty before this filing date? Find Prior Art